[Multicentric clinical proof of a new oral antidiabetic glisoxepide (BS 4231). II. Proof of activity in the management of adult onset diabetes].
D000328:Adult; D000368:Aged; D001381:Azepines / Q000627:therapeutic use*; D001786:Blood Glucose; D001794:Blood Pressure; D001835:Body Weight; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D010080:Oxazoles / Q000627:therapeutic use*; D013223:Statistics as Topic; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D013997:Time Factors
D001381:Azepines; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D008055:Lipids; D010080:Oxazoles; D013453:Sulfonylurea Compounds
Multizentrische klinische Prüfung des neuen oralen Antidiabetikums Glisoxepid (BS 4231). II. Prüfung der Wirksamkeit in der Behandlung des Erwachsenen-Diabetes